Literature DB >> 2501391

IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells.

E Maraskovsky1, W F Chen, K Shortman.   

Abstract

A filler cell-free limiting-dilution microculture system has been developed for the expansion and differentiation of a high proportion of single CD4-CD8+ T cells into cytolytic T cell (CTL) clones. The stimulus used was PMA together with the calcium ionophore ionomycin. The growth and differentiation factors were rIL-2, together with either a Con A-stimulated spleen cell supernatant (CAS) or rIFN-gamma. CTL activity was monitored by an autoradiographic 111In-release assay. With CAS and rIL-2 present, 50% of all potential precursors (CTL-p) produced cytolytic clones. Substitution of rIFN-gamma for CAS gave a similar efficiency with up to 42% of CTL-p producing cytolytic clones. rIL-2 alone allowed only a small proportion (6%) of CD4-CD8+ T cells to become cytolytic clones. Addition of rIL-2 and rIFN-gamma at various stages of the culture demonstrated that IL-2 was required throughout, but exogenous IFN-gamma was required only during the early stages. It is concluded that for at least 40% of all CTL-p, the lymphokines IL-2 and IFN-gamma are essential and act in synergy to induce proliferation and differentiation into CTL.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2501391

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  56 in total

Review 1.  Antibody-cytokine fusion proteins: applications in cancer therapy.

Authors:  Elizabeth Ortiz-Sánchez; Gustavo Helguera; Tracy R Daniels; Manuel L Penichet
Journal:  Expert Opin Biol Ther       Date:  2008-05       Impact factor: 4.388

2.  Gamma interferon is not required for mucosal cytotoxic T-lymphocyte responses or heterosubtypic immunity to influenza A virus infection in mice.

Authors:  H H Nguyen; F W van Ginkel; H L Vu; M J Novak; J R McGhee; J Mestecky
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 3.  Gene therapy for cystic fibrosis: challenges and future directions.

Authors:  J M Wilson
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

4.  Correlation of the therapeutic effect of activated tumor-draining lymph node cells with specific interferon-gamma production in vitro.

Authors:  S Sameshima; K Sakai; H Nagawa; N Tsuno; J Kitayama; T Muto
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

5.  Immunological memory induced by genetically transduced tumor cells.

Authors:  M M Dar; Z Abdel-Wahab; C E Vervaert; T Darrow; J Barber; H F Seigler
Journal:  Ann Surg Oncol       Date:  1996-05       Impact factor: 5.344

Review 6.  The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications.

Authors:  Jiemiao Hu; Jun Yan; Ganesh Rao; Khatri Latha; Willem W Overwijk; Amy B Heimberger; Shulin Li
Journal:  Int Rev Immunol       Date:  2014-09-26       Impact factor: 5.311

7.  Increased anti-tumor effect by a combination of HSV thymidine kinase suicide gene therapy and interferon-gamma/GM-CSF cytokine gene therapy in CT26 tumor model.

Authors:  Sung Hyun Yang; Tae Keun Oh; Seung Taik Kim
Journal:  J Korean Med Sci       Date:  2005-12       Impact factor: 2.153

8.  Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc/CD28/CD3zeta gene tranfected T cells.

Authors:  Yihu Zheng; Kang Yu; Jimei Du; Lei Jiang; Shenghui Zhang; Yixiang Han; Panpan Yu; Yingxia Tan
Journal:  J Exp Clin Cancer Res       Date:  2010-09-03

9.  Complete response to high-dose IL-2 and enhanced IFNγ+Th17 :  TREG ratio in a melanoma patient.

Authors:  Maggie L Diller; Ragini R Kudchadkar; Keith A Delman; David H Lawson; Mandy L Ford
Journal:  Melanoma Res       Date:  2016-10       Impact factor: 3.599

10.  Lymphokine production by human melanoma tumor-infiltrating lymphocytes.

Authors:  M A Salmeron; T Morita; H Seki; C D Platsoucas; K Itoh
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.